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Aims The aim of this study is to quantify altered myocardial calcium handling in non-ischaemic cardiomyopathy using
magnetic resonance imaging.
...................................................................................................................................................................................................
Methods
and results
Patients with dilated cardiomyopathy (n = 10) or hypertrophic cardiomyopathy (n = 17) underwent both gadolinium
and manganese contrast-enhanced magnetic resonance imaging and were compared with healthy volunteers
(n = 20). Differential manganese uptake (Ki) was assessed using a two-compartment Patlak model. Compared with
healthy volunteers, reduction in T1 with manganese-enhanced magnetic resonance imaging was lower in patients
with dilated cardiomyopathy [mean reduction 257 ± 45 (21%) vs. 288 ± 34 (26%) ms, P < 0.001], with higher T1 at
40 min (948 ± 57 vs. 834 ± 28 ms, P < 0.0001). In patients with hypertrophic cardiomyopathy, reductions in T1 were
less than healthy volunteers [mean reduction 251 ± 86 (18%) and 277 ± 34 (23%) vs. 288 ± 34 (26%) ms, with and
without fibrosis respectively, P < 0.001]. Myocardial manganese uptake was modelled, rate of uptake was reduced
in both dilated and hypertrophic cardiomyopathy in comparison with healthy volunteers (mean Ki 19 ± 4, 19 ± 3,
and 23 ± 4 mL/100 g/min, respectively; P = 0.0068). In patients with dilated cardiomyopathy, manganese uptake rate
correlated with left ventricular ejection fraction (r2 = 0.61, P = 0.009). Rate of myocardial manganese uptake demon-
strated stepwise reductions across healthy myocardium, hypertrophic cardiomyopathy without fibrosis and hyper-
trophic cardiomyopathy with fibrosis providing absolute discrimination between the healthy myocardium and
fibrosed myocardium (mean Ki 23 ± 4, 19 ± 3, and 13 ± 4 mL/100 g/min, respectively; P < 0.0001).
...................................................................................................................................................................................................
Conclusion The rate of manganese uptake in both dilated and hypertrophic cardiomyopathy provides a measure of altered
myocardial calcium handling. This holds major promise for the detection and monitoring of dysfunctional myocar-
dium, with the potential for early intervention and prognostication.
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Introduction
Cardiomyopathy represents a broad spectrum of clinical diseases
which cause myocardial dysfunction leading to symptoms and signs of
congestive cardiac failure. Whilst the aetiology is well characterized
in ischaemic cardiomyopathy, non-ischaemic cardiomyopathies en-
compass a broad range of diseases that include genetic, acquired, and
mixed aetiologies.1 Advances in cardiac magnetic resonance imaging
can help establish the aetiology of, and risk stratify patients with,
dilated cardiomyopathy using techniques that include detection of fi-
brosis with late gadolinium enhancement and global longitudinal
strain analysis.2,3 However, there remains a relative lack of features
discriminating the causes of some forms of non-ischaemic cardiomy-
opathy as well as the assessment of myocardial pathophysiology, dis-
ease severity, and disease progression.2,4
Hypertrophic cardiomyopathy represents another population of
patients at-risk of heart failure, but with a distinct pathophysiology.
These genetic disorders of sarcomeric proteins cause abnormal myo-
cyte architecture and increased left ventricular wall thickness result-
ing in diastolic and systolic dysfunction.5 Tissue characterization with
cardiac magnetic resonance imaging has improved discrimination of
hypertrophic cardiomyopathy phenocopies and defines macroscopic
myocardial fibrosis with late gadolinium enhancement.3,6,7 T1 map-
ping with extracellular volume quantification has also shown potential
in adding to current risk stratification.8,9 However, the techniques of
late gadolinium enhancement and pre- and post-contrast T1 mapping
do not provide information on cardiomyocyte function due to the
extracellular distribution of gadolinium-based contrast media. This
limits the ability to detect very early myocardial dysfunction and
understand the in vivo pathophysiology of different disease states.
Manganese-enhanced magnetic resonance imaging has been well
described in animal and human models showing the potential to as-
sess myocardial calcium handling directly.10–12 Here, manganese
behaves as an analogue of calcium and is rapidly taken up by viable
myocardium.13,14 We have shown that manganese enhancement
tracks with myocardial contractility and uptake is absent following
acute myocardial infarction.10 Furthermore, we have demonstrated
that direct quantification of myocardial viability using manganese-
enhanced magnetic resonance imaging is directly comparable with
that of 18F-fluorodeoxyglucose positron emission tomography.12
However, despite these and other studies,10,15–17 it has yet to be
established whether manganese-enhanced magnetic resonance imag-
ing can detect alterations in myocardial calcium handling and con-
tractility in non-ischaemic cardiomyopathies. The objective of this
proof-of-concept study was therefore to evaluate the ability of
manganese-enhanced magnetic resonance imaging to detect altered
myocardial calcium handling in patients with dilated or hypertrophic
cardiomyopathy.
Methods
This was a single-centre open-label observational cohort study
(NCT03607669, EudraCT number 2016-003782-25) which was carried
out in accordance with the Declaration of Helsinki, the favourable ethical
opinion of the South East Scotland Research Ethics Committee 2 (17/SS/
0055) and with written informed consent from all participants.
Patients
Adult patients (>_18 years of age) with non-ischaemic dilated cardiomyop-
athy and hypertrophic cardiomyopathy were recruited from the
Edinburgh Heart Centre between May 2018 and July 2019. Diagnosis of
dilated cardiomyopathy and hypertrophic cardiomyopathy was based on
echocardiography or magnetic resonance imaging according to European
Society of Cardiology guidelines.18Non-ischaemic dilated cardiomyop-
athy was defined by the presence of impaired left ventricular systolic func-
tion (ejection fraction <_50% within 12 months) and left ventricular
dilatation (left ventricular end-diastolic volume >117% adjusted for age
and body-surface area), in the absence of abnormal loading conditions
(hypertension and valvular disease) and coronary artery disease.18
Hypertrophic cardiomyopathy was defined as left ventricular hyper-
trophy (left ventricular wall thickness >_15 mm in any segment) in the ab-
sence of haemodynamic stresses.18 Presence of diastolic dysfunction in
hypertrophic cardiomyopathy was based was defined on transthoracic
echocardiography as per British Society of Transthoracic
Echocardiography guidelines.19
All patients were required to have New York Heart Association
Classes I–III heart failure, with stable symptoms and no change in mainten-
ance therapy in the preceding month. Healthy volunteers were recruited
as a control population and had no known pre-existing medical condi-
tions. Exclusion criteria for all participants were any contraindication to
magnetic resonance imaging, contraindications to manganese dipyridoxyl
diphosphate administration (high degree atrioventricular block, history of
torsades de pointes or prolonged QTc interval, obstructive liver disease,
maintenance on calcium-channel blockade, or digoxin therapy), renal fail-
ure (estimated glomerular filtration rate <30 mL/min/1.73 m2), New
York Heart Association Class IV heart failure, and women of child-
bearing potential without a negative pregnancy test.
Magnetic resonance imaging
Magnetic resonance imaging was performed using a Siemens Magnetom
Skyrafit 3 T scanner (Siemens Healthineers, Erlangen, Germany), with a
dedicated 60-channel body array coil. All study participants underwent
scanning with both late gadolinium enhancement and manganese-
enhanced magnetic resonance imaging, >_48 h apart and in random order.
Images were acquired with ECG-gating and were breath-held in expir-
ation. Cine imaging was acquired with retrospective ECG-gating, with
standard steady-state free precession sequences (TrueFISP) in long and
short-axis orientations as described previously.10 T1 mapping was per-
formed prospectively with shortened modified Look-Locker inversion re-
covery (WIP #1048 Siemens Healthineers). Quantitative estimation of
T1 was performed in full short-axis stack from mitral valve annulus to
apex and standard long-axis slices, with additional slices positioned ap-
propriately to characterize pathology (repetition time = 388.8 ms; echo
time = 1.07 ms; matrix = 256 115; slice thickness = 8 mm with 1.6 mm
gap). T1 relaxation times were estimated before and after administration
of gadolinium20 and manganese-based contrast media.
Late gadolinium enhancement
Late-gadolinium enhancement images were acquired following intraven-
ous administration of gadobutrol (0.1 mmol/kg; Gadovist, Bayer,
Germany) using a single breath held phase-sensitive inversion recovery
short-axis stack, and long axis orientations (repetition time = 820 ms;
echo time = 1.04 ms; matrix = 192 81; slice thickness = 8 mm with
2 mm gap). A standardized inversion time of 400 ms was used and
adjusted as required for optimal myocardial nulling. Post-contrast
T1 mapping was performed prospectively with short-axis shortened
modified Look-Locker inversion recovery stack 20 min post-contrast.
2 N. Spath et al.
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Serum haematocrit measured on the day of scanning was used to calcu-
late extracellular volume.
Manganese-enhanced magnetic resonance imaging
Manganese-enhanced magnetic resonance imaging was achieved using
intravenous infusion of manganese dipyridoxyl diphosphate [5mmol/kg
(0.1 mL/kg) at 1 mL/min; Exova SL Pharma, Wilmington, DE, USA]. T1
mapping was performed pre-contrast with full short-axis shortened
modified Look-Locker inversion recovery stack as above (Supplementary
data online, Figure S1). For patients, a single short-axis slice was identified
by the supervising cardiologist, guided by the late gadolinium enhance-
ment, native T1 maps and cine images to represent hypertrophied myo-
cardium. For patients with hypertrophic cardiomyopathy, regions of
maximal hypertrophy and fibrosis were selected and for dilated cardio-
myopathy, a mid-ventricular short-axis slice was selected. A single short-
axis T1 mapping was then performed at this slice location every 2.5 min
for 40 min after starting contrast infusion, at which point a full short-axis
shortened modified Look-Locker inversion recovery stack was repeated
post-contrast (Supplementary data online, Figure S1). For healthy volun-
teers, a mid-ventricular slice was chosen for serial T1 mapping after man-
ganese dipyridoxyl diphosphate infusion. Heart rate and blood pressure
were measured for the duration of the scans.
Image analysis
All analysis of T1 maps, late-gadolinium enhancement and cine-derived
volumetric and functional sequences was performed using Circle CVI
(Circle Cardiovascular Imaging, CVI42 v5.3.6, Calgary, Canada) as
described previously.10 The operator was blinded to patients details and
manganese-enhanced images were analysed separately from late-
gadolinium images.
Kinetic modelling
Functional impairment by reduced calcium-channel activity was assessed
on manganese-enhanced magnetic resonance imaging T1 maps. To quan-
tify change in T1 over time, regions of interest were drawn in areas of
pathological myocardium applied to all slices from 0 to 40 min. In patients
with hypertrophic cardiomyopathy, regions of interest were drawn in
regions of macroscopic fibrosis by late gadolinium enhancement as well
as pathologically hypertrophied myocardium without clear fibrosis and
non-hypertrophied non-fibrosed myocardium. For patients with dilated
and diabetic cardiomyopathy, regions of interest were drawn in the mid-
ventricular septal segments.
In brief, the model consists of (i) a reversible compartment (ve), com-
parable to intravascular and interstitial space and (ii) an irreversible com-
partment (vi) where irreversible accumulation of the contrast agent is
anticipated, comparable to the intracellular space. The arterial concentra-
tion (derived from blood pool T1) represents contrast agent delivery
into myocardial tissue and constitutes the arterial input function
(Supplementary data online, Figure S2).
Skjöld et al.21 have previously derived a Patlak model adaptation for
cardiac manganese-enhanced magnetic resonance imaging, demonstrating
an apparent unidirectional influx constant (Ki) for the transfer of manga-
nese from plasma to irreversible compartments (vi) can be measured
using Eq. (1):
CtðtÞ
CaðtÞ
¼ Ki
Ð t
0 Ca sð Þds
CaðtÞ
þ ve (1)
where Ct and Ca are the manganese concentration in myocardial tissue
and blood pool (arterial input function) respectively. This expression is
equivalent to the Patlak formulation22 and describes that if a contrast me-
dium is irreversibly trapped in the tissue within the imaging time frame,
the instantaneous tissue concentration divided by the instantaneous ar-
terial concentration plotted against the integrated arterial concentration
divided by the instantaneous arterial concentration, will result in lineariza-
tion of the data. The gradient of this line represents the apparent unidir-
ectional influx constant Ki, which in turn equals:
Ki ¼ k1 k3
k2þ k3 (2)
where k1, k2, and k3 are the individual rate constants of the compartmen-
tal model presented (Supplementary data online, Figure S2). To derive the
manganese concentrations Ct and Ca as a function of time to be used in
Eq. (1), the following equation was used:
R1 tð Þ ¼ R1 0ð Þ þ r1CðtÞ (3)
where R1 = 1/T1, R1(0) is the native longitudinal relaxation rate and R1(t) is
the longitudinal relaxation rate at time t of manganese contrast enhance-
ment, r1 is the relaxivity and C(t) is the concentration of the contrast agent
at time t. Using Eq. (3), Ct and Ca were calculated for each successive T1
map derived in the tissue and blood pool before, during and after contrast
infusion for the 40 min period of the manganese-enhanced magnetic reson-
ance imaging protocol (Supplementary data online, Figure S1). The Patlak
model employed here has previously been shown as an effective method of
estimating intracellular influx of manganese in the context of imaging with
MnDPDP in the same dose and formulation used in the present study.21,22
Contrast kinetics modelling was performed using in-house software20
developed in Matlab (Version R2016a, MathWorks Inc., Natick, MA,
USA) based on a two-compartment model identical to that previously
applied to cardiac manganese-enhanced magnetic resonance imaging
with manganese dipyridoxyl diphosphate.21
Statistical analysis
All statistical analysis was performed with GraphPad Prism (GraphPad
Software v8.0.2, San Diego, CA, USA). Continuous data were assessed
for normality using the D’Agostino-Pearson test. Categorical baseline var-
iables were compared using Fisher’s exact test. Values are mean ± stand-
ard deviation unless otherwise stated. To compare cardiac function and
change in myocardial manganese uptake in patients and healthy volun-
teers, volumetric assessment, and parametric mapping values were com-
pared using paired or unpaired t-tests, Wilcoxon or Mann–Whitney
tests, and analysis of variance and co-variance or Kruskal–Wallis tests as
appropriate. Statistical significance was taken as two-sided P < 0.05.
Results
Ten patients with non-ischaemic dilated cardiomyopathy and 20
patients with hypertrophic cardiomyopathy were recruited. Three
patients in the hypertrophic cardiomyopathy cohort withdrew (two
had claustrophobia and one developed high degree atrioventricular
block prior to infusion), leaving 17 who completed the study proto-
col. A cohort of 20 healthy volunteers was used as a contemporan-
eous control group (Table 1).23 All patients completed late
gadolinium-enhanced and manganese-enhanced magnetic resonance
imaging scans, at least 48 h apart.
Most patients had idiopathic non-ischaemic dilated cardiomyop-
athy, with three with history of familial dilated cardiomyopathy. Over
half of patients with hypertrophic cardiomyopathy had genetic testing
with seven gene positive cases. The patient groups were older than
healthy volunteers but were well matched for gender and body mass
index (Table 1). Patients had higher left ventricular mass index and
Manganese-enhanced magnetic resonance imaging 3
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..extracellular volume fraction (P = 0.0002 and P < 0.0001 respectively,
Table 2).
Administration of manganese dipyridoxyl diphosphate was well
tolerated by all participants, with a mean infusion time of 8 min. No
adverse events or side-effects were recorded by 7 days of follow-up
in any participant. There were no changes in ECG variables, heart
rate, or blood pressure during infusion of manganese dipyridoxyl di-
phosphate (Supplementary data online, Figure S3, all P > 0.1).
Patients with non-ischaemic dilated
cardiomyopathy
In comparison with healthy volunteers, patients with dilated
cardiomyopathy had lower ejection fraction and higher cardiac
volumes (Table 2). Native myocardial T1 was higher in patients with
non-ischaemic dilated cardiomyopathy (1204± 70 vs. 1123± 36 ms;
Figure 1). During manganese dipyridoxyl diphosphate infusion, myo-
cardial T1 values demonstrated a rapid initial descent followed by a
gradual and sustained reduction that was similar to the myocardium
of healthy volunteers. However, mean reductions in T1 values were
less marked in patients with dilated cardiomyopathy [mean reduction
257± 45 (21%) vs. 288 ± 34 (26%) ms, ANCOVA P = 0.03], resulting
in higher T1 values at 40 min (948 ± 57 vs. 834 ± 28 ms, ANCOVA
P = 0.0011; Figure 2).
Kinetic modelling demonstrated a lower rate of myocardial manga-
nese uptake in patients with dilated cardiomyopathy compared with
healthy volunteers (mean Ki 19± 4 and 23 ± 4 mL/100 g/min,
......................................................................................................
....................................................................................................................................................................................................................
Table 1 Baseline clinical characteristics of study participants
Healthy volunteers (n 5 20) Patients with non-ischaemic cardiomyopathy (n 5 27)
Dilated cardiomyopathy
(n 5 10)
Hypertrophic cardiomyopathy
(n 5 17)
Male 13 (65) 6 (60) 10 (59)
Age (years) 42 ± 11 57 ± 10 65 ± 7
Body-mass index (kg/m2) 26.0 ± 2.9 28.1 ± 3.1 29.1 ± 5.4
Aetiology
Idiopathic — 6 (60) —
Genetic — 3 (30) 17(100)
Drug induced — 1 (10) —
Genetic testing
Positive — 3 (30) 7 (41)
Negative — 1 (10) 4 (24)
Not done — 6 (60) 6 (35)
Echocardiographic Findings
LV systolic dysfunction 0 (0) 10 (100) 0 (0)
LV diastolic dysfunction 0 (0) — 17 (100)
Past medical history —
Hypertension 0 1 (10) 2 (12)
Ischaemic heart disease 0 2 (20) 1 (6)
Hypercholesterolaemia 0 2 (20) 0
Atrial fibrillation/flutter 0 1 (10) 2 (12)
Cerebrovascular disease 0 1 (10) 0
Diabetes mellitus 0 1 (10) 0
Medications
Antiplatelet therapy 0 5 (50) 2 (12)
b-Blocker therapy 0 10 (100) 8 (47)
ACE inhibitor/ARB therapy 0 6 (60) 6 (35)
MRA therapy 0 10 (100) 0
Statin therapy 0 5 (50) 2 (12)
Anticoagulation therapy 0 0 0
Smoking status
Non-smoker 18 6 (60) 13 (76)
Ex-smoker 2 3 (30) 4 (24)
Current smoker 0 1 (10) 0
n (%) or mean ± standard deviation.
LV, left ventricular; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist.
4 N. Spath et al.
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..respectively, P = 0.0068; Figure 3). The rate of myocardial manganese
uptake (by influx constant) correlated with left ventricular ejection
fraction in patients with dilated cardiomyopathy (r2 = 0.61, P = 0.009,
Figure 4).
Patients with hypertrophic
cardiomyopathy
In comparison with healthy volunteers, patients with hypertrophic
cardiomyopathy had higher ejection fraction, lower cardiac volumes
and diastolic dysfunction to varying degrees (Tables 1 and 2). Native
T1 values of the myocardium were higher in patients with hyper-
trophic cardiomyopathy compared with healthy volunteers
(1183± 42 vs. 1123 ± 36 ms; Figure 1). In patients, there were discrete
foci of bright late gadolinium enhancement indicating dense fibrosis
which showed markedly different T1 profiles following manganese
dipyridoxyl diphosphate infusion, with T1 recovering towards base-
line values similar to the blood pool (Figure 5). In areas of hypertro-
phied myocardium without discrete late gadolinium enhancement,
T1 values following manganese dipyridoxyl diphosphate infusion
demonstrated a gradual but continued reduction in T1 values over
the 40-min period. Manganese-enhanced T1 values were higher in
regions with and without discrete late gadolinium enhancement
(908 ± 47 and 1140± 208 vs. 834± 28 ms in myocardium of healthy
volunteers, both ANCOVA P < 0.0001). Mean reductions in T1 were
lower in patients with and without fibrosis compared with healthy
volunteers [mean reduction 252 ± 86 (18%) and 277± 34 (23%) vs.
288 ± 34 (26%) ms respectively, ANCOVA P < 0.001].
Kinetic modelling of myocardial manganese influx demonstrated
stepwise reductions across healthy myocardium, hypertrophic car-
diomyopathy without fibrosis and hypertrophic cardiomyopathy with
fibrosis, providing clear demarcation between the healthy
myocardium and fibrosed myocardium (mean Ki 23± 4, 19± 3 and
13 ± 4 mL/100 g/min; ANCOVA P < 0.0001; Figure 3).
Discussion
This is the first description of manganese-enhanced magnetic
resonance imaging T1 mapping to detect abnormal myocardial
cellular physiology in patients with non-ischaemic dilated cardio-
myopathy or hypertrophic cardiomyopathy. Our findings suggest
that alterations in myocardial calcium handling in cardiomyopa-
thies can be detected and are associated with left ventricular sys-
tolic dysfunction as well as regions of fibrosis and scar formation.
This novel approach has major potential for the detection,
investigation, and management of patients with a range of
cardiomyopathies.
Myocardial contraction is dependent on excitation-contraction
coupling for which calcium homeostasis is essential. Dysfunctional
calcium handling is a central feature of left ventricular dysfunction
in patients with dilated cardiomyopathy, with alterations in cal-
cium handling proteins24 leading to reduced myocardial contract-
ile function.25,26 We have shown that manganese-enhanced
magnetic resonance imaging detects clear abnormalities in myo-
cardial calcium handling of patients with non-ischaemic dilated
cardiomyopathy. Moreover, kinetic modelling demonstrated a
direct correlation between myocardial manganese uptake and
left ventricular ejection fraction. As such, this study confirms
the presence of dysfunctional calcium handling in the myocardium
of patients with non-ischaemic dilated cardiomyopathy.
Furthermore, it provides a non-invasive imaging technique that
has the potential to be used as a marker for risk stratification, dis-
ease progression, and response to therapy.5
.....................................................................
....................................................................................................................................................................................................................
Table 2 Baseline magnetic resonance imaging characteristics of study participants
Healthy control
(n 5 20)
Non-ischaemic cardiomyopathy (n 5 27) ANOVA
P-value
P-Value
(DCM vs. HCM)
DCM (n 5 10) HCM (n 5 17)
LVEDVI (mL/m2) 74.7 ± 14.4 111.4 ± 39.4 62.9 ± 10.1 <0.0001 0.00052
LVESVI (mL/m2) 26.8 ± 7.3 74.0 ± 39.2 15.2 ± 4.4 <0.0001 0.00002
Stroke volume index (mL/m2) 47.9 ± 9.1 37.3 ± 8.3 47.7 ± 7.2 0.0011 0.002
Ejection fraction (%) 64.4 ± 5.5 34.7 ± 13.6 76.2 ± 4.8 <0.0001 <0.0001
LV mass index (g/m2) 57.9 ± 13.1 76.8 ± 20.7 86.7 ± 27.1 0.0002 0.329
Extracellular volume (%) 27.1 ± 3.6 33.8 ± 2.7 31.3 ± 2.5 <0.0001 0.022
Native T1-septum (ms) 1123 ± 36 1206 ± 57 1183 ± 42 <0.0001 0.239
MEMRI T1-septum (ms) 835 ± 28 927 ± 43 899 ± 34 <0.0001 0.073
Native T1-fibrosis (ms) — — 1392 ± 215
MEMRI T1-fibrosis (ms) — — 1141 ± 209
Late gadolinium enhancement (% LV) — — 13 ± 4
Influx constant (Ki/mL/100 g/min)
Myocardial septum 23 ± 4 19 ± 4.0 19 ± 3 <0.0001 0.941
Fibrosis — — 13 ± 4
Mean ± standard deviation or median ± interquartile range.
HCM, hypertrophic cardiomyopathy; DCM, non-ischaemic cardiomyopathy, LVEDVI, indexed left ventricular end-diastolic volume; LVESVI, indexed left ventricular end-systolic
volume; MEMRI, manganese-enhanced magnetic resonance imaging; LV, left ventricular; ANOVA, analysis of variance.
Manganese-enhanced magnetic resonance imaging 5
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..Detection of myocardial fibrosis with late gadolinium enhance-
ment and global measures of cardiac performance, such as left ven-
tricular ejection fraction, can help in monitoring disease and
prognostication.27 However, subtle myocyte dysfunction is difficult
to detect and could be beneficial in highlighting patients who are at
risk of deteriorating left ventricular function: a feature which is associ-
ated with poor cardiac outcomes.28 In the present study, manganese-
enhanced magnetic resonance imaging detected altered manganese
uptake reflecting abnormal calcium handling in patients with severe
phenotypes of non-ischaemic cardiomyopathy. Manganese-enhanced
magnetic resonance imaging therefore has potential to go beyond
myocardial fibrosis imaging and identify subclinical changes in calcium
handling, a feature that could also be utilized in the early detection of
patients who are at risk of heart failure prior to developing symptoms
or signs of overt left ventricular dysfunction. This needs to be con-
firmed in future studies across a range of clinical phenotypes of car-
diac disease.
In patients with hypertrophic cardiomyopathy, the left
ventricular ejection fraction was preserved or supranormal with
diastolic dysfunction seen in all cases. Despite this, myocardial
manganese-enhanced magnetic resonance imaging T1 and native T1
were higher in regions of hypertrophy without discrete late gadolin-
ium enhancement. The rate of manganese influx into pathologically
hypertrophied myocardium was reduced. This indicates the presence
of abnormal myocardial calcium handling in hypertrophied myocar-
dium with predominantly diastolic impairment. Diastolic dysfunction
in hypertrophic cardiomyopathy is multifactorial, and includes pro-
longed and disordered ventricular relaxation, decreased chamber
compliance, and abnormal calcium cycling.29 Increases in calcium
entry through L-type calcium channels combined with reduced cal-
cium extrusion and lower sarcoplasmic reticulum calcium adenosine
triphosphotase expression result in elevated intracellular calcium
concentration. Furthermore, dysfunctional calcium handling appears
to precede alterations in metabolic activity30 and is associated with
an increased risk of arhythmogenesis.31 As such, manganese-
enhanced magnetic resonance could be used to detect the earlier
signs of altered calcium handling, a surrogate marker of disease pro-
gression and prognostication.32
In patients with hypertrophic cardiomyopathy, the recovery of
myocardial T1 values within dense regions of severe fibrosis was
Figure 1 Late gadolinium enhanced, native T1 and manganese-enhanced magnetic resonance imaging in healthy volunteers and patients with non-
ischaemic cardiomyopathy. Representative late gadolinium enhancement, native and manganese-enhanced magnetic resonance imaging T1 mapping in
(A) healthy volunteer, (B) patient with dilated cardiomyopathy, and (C) patient with hypertrophic cardiomyopathy following manganese dipyridoxyl di-
phosphate infusion.
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..similar to that observed in the blood pool. We have previously
described a similar profile of recovery in regions of transmural acute
myocardial infarction.10 This is consistent with the marked reduction
in manganese uptake due to the presence of non-viable myocardium
and non-functional fibrotic tissue scar. This ability to differentiate and
track viable myocardium could play a role in the assessment of re-
versible causes of cardiomyopathies which show transient myocardial
dysfunction.
After administration, biotransformation of manganese dipyridoxyl
diphosphate occurs by dephosphorylation and transmetallation with
zinc, enabling intracellular manganese uptake as demonstrated
in vitro where tissue uptake and renal clearance occur
rapidly.33,34Manganese-based contrast media have previously been
reported to cause acute myocardial suppressant effects. In preclinical
studies, unchelated manganese chloride produced very high free
manganese ion concentrations causing negative inotropy and cardio-
vascular instability.35 We used a custom manufactured dipyridoxyl di-
phosphate chelation of manganese which markedly reduces free
unbound manganese ions. This formulation of manganese was previ-
ously approved for clinical use (TeslascanVR )36 but was withdrawn
from the US market in 200337 and the EU market in 201038 because
it was not commercially viable. In Phase 3 clinical trials,39 mild to
moderate side effects were reported in 1–7% of participants and
included headache and flushing. In the present study, we observed no
adverse events or side effects despite including patients with marked
left ventricular dysfunction and ejection fractions of <25%.
Furthermore, there were no instances of haemodynamic comprom-
ise or cardiac arrhythmia during, or up to 30 min following, manga-
nese administration, and no adverse symptoms or side effects
reported at 7-day follow-up. This suggests that this formulation of
manganese is safe even in those with left ventricular systolic
dysfunction.
What are the clinical implications of our findings? In this study, we
have undertaken manganese-enhanced magnetic resonance imaging
T1 mapping in two populations of non-ischaemic cardiomyopathies
and have demonstrated its ability to detect and to quantify altered
myocardial calcium handling over and above existing methods of
identifying myocardial fibrosis. This is not specific to non-ischaemic
cardiomyopathies and could potentially be used to assess a wider
range of cardiomyopathy phenotypes, although this has yet to be
established. As expected, manganese-enhanced magnetic resonance
imaging correlated with a range of left ventricular ejection fraction
suggesting it has potential to track and to quantify more subtle grada-
tions of myocardial dysfunction. Late-gadolinium enhancement and
extracellular volume fraction imaging relies on abnormal tissue struc-
ture to identify regions of pathological myocardium. The ability of
manganese-enhanced magnetic resonance imaging to detect altered
calcium handling over time and quantify cellular myocardial function
directly may transform our ability to assess myocardial function dir-
ectly, enabling early detection, prognostication and assessment of
Figure 2 Native and manganese-enhanced magnetic resonance imaging T1 profiles in patients with non-ischaemic cardiomyopathy.
Representative mean T1 profiles of myocardial regions of interest over time following manganese dipyridoxyl diphosphate in (A) patient with dilated
cardiomyopathy (green, n = 10), compared with healthy volunteers (blue, n = 20) and (B) patient with hypertrophic cardiomyopathy (red, n = 17),
compared with healthy volunteers (blue, n = 20). Manganese dipyridoxyl diphosphate was infused from time 0 to 10 min (dashed line). Error bars are
standard deviation of the mean.
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treatment efficacy. With optimization, this technique has potential to
allow individualization of heart failure treatment, targeting optimal
therapy to those most likely to benefit. Furthermore, early detection
of altered calcium-handling in established or at-risk cardiomyopathy
may enable earlier initiation of preventative therapy than previously
possible, with the potential to improve long-term clinical outcomes.
We therefore suggest that further investigation of reversible
cardiomyopathies, such as stress cardiomyopathy and myocarditis, is
a crucial next step to further our understanding of calcium dysfunc-
tion seen in the acute and chronic setting.
Our study has several limitations that should be considered. First,
there have been prior concerns regarding toxicity as well as current
lack of a marketed formulation of manganese. The chelated form
used here retains the necessary properties for intracellular myocar-
dial imaging whilst cardiac function remains uncompromised as dem-
onstrated by the absence of haemodynamic or arrhythmic effects in
published safety data.40,41 Furthermore, we anticipate that the avail-
ability of such agents will increase following continued demonstration
of its clinical and research utility. Secondly, calcium channel antago-
nists and digoxin reduce uptake of manganese dipyridoxyl diphos-
phate and as a result these medications were excluded. However,
patients were maintained on other cardiac medications including b-
blocker, angiotensin converting enzyme inhibitor, mineralocorticoid
receptor antagonist, statin, and anti-platelet therapies. We cannot ex-
clude an effect of these medications on our findings but in our previ-
ous work in patients with acute myocardial infarction, concomitant
use of these medications did not influence manganese uptake in the
myocardium remote from the site of infarction.23 Thirdly, as a proof-
of-concept study, the sample size is small, reflecting absence of prior
data in this area on which to base accurate power calculations as the
variance was unknown. Data from this study will facilitate ongoing
and future studies to confirm the translational potential of this ap-
proach. Finally, we cannot rule out that calcium handling deteriorates
with age and the fact that control subjects were younger than those
Figure 3 Differential manganese uptake in patients with non-ischaemic cardiomyopathy. Patlak plot (A) and kinetic modelling of manganese uptake
(B) (Ki, influx constant) in patients with non-ischaemic cardiomyopathy. Each line represents a single representative individual. Healthy volunteers
(blue), patients with dilated cardiomyopathy (green), patients with hypertrophic cardiomyopathy without fibrosis (red), and patients with
hypertrophic cardiomyopathy with fibrosis (black).
Figure 4 Manganese uptake vs. left ventricular ejection fraction in
patients with dilated cardiomyopathy. Myocardial manganese up-
take (by influx constant) in patients with dilated cardiomyopathy.
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..with cardiomyopathy could explain some of the observed reductions
in manganese uptake. However, we found no correlation between
age and manganese uptake in the healthy volunteers or our individual
patient cohorts (data not shown).
Conclusion
We have described the first proof-of-concept T1 mapping study of
manganese-enhanced magnetic resonance imaging in patients with
non-ischaemic cardiomyopathy. Using kinetic modelling, we have
shown that manganese-enhanced magnetic resonance imaging can
detect dysfunctional myocardial calcium handling and can directly dis-
tinguish normal from pathological myocardium. We believe that
manganese-enhanced magnetic resonance imaging holds major
promise for the detection and monitoring of disease progression in
non-ischaemic cardiomyopathy, with the potential for early interven-
tion, tracking of response to therapy, and overall prognostication.
Finally, its application to other areas of disease, such as reversible car-
diomyopathies or detection of sub-clinical cardiomyopathies, war-
rants further investigation.
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